BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
IPO Year: 2015
Exchange: NASDAQ
Website: biondvax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/26/2022 | $7.00 | Buy | Aegis Capital |
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3/A - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
3 - BiondVax Pharmaceuticals Ltd. (0001611747) (Issuer)
Aegis Capital initiated coverage of BiondVax Pharmaceuticals with a rating of Buy and set a new price target of $7.00
EFFECT - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
F-3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
D - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
424B3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
424B3 - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)